Actively Recruiting
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Led by Kuirong Jiang · Updated on 2024-04-11
53
Participants Needed
1
Research Sites
225 weeks
Total Duration
On this page
Sponsors
K
Kuirong Jiang
Lead Sponsor
C
CSPC Ouyi Pharmaceutical Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the efficacy and safety of irinotecan liposome injection in combined with oxaliplatin plus tegafur (NASOX) for postoperative adjuvant chemotherapy for pancreatic cancer.
CONDITIONS
Official Title
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- ECOG performance status 0 or 1
- Histologically confirmed resected ductal pancreatic adenocarcinoma with macroscopic complete resection (R0 and R1)
- Life expectancy of greater than or equal to 6 months
- Able and willing to provide a written informed consent
You will not qualify if you...
- Patients who cannot eat orally and have gastric emptying disorder after surgery
- Patients with moderate diarrhea: diarrhea 4 times per day; moderate and severe effluents from stoma increased; or diarrhea that limits activities of daily living
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
FirstNanjingMU
Nanjing, Jiangsu, China, 025
Actively Recruiting
Research Team
K
KuiRong Jiang, archiater
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here